Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $21.44, for a total value of $142,940.48. Following the sale, the chief operating officer now owns 323,310 shares in the company, valued at $6,931,766.40. The trade was a 2.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Anish Patel also recently made the following trade(s):
- On Friday, February 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.93, for a total value of $146,207.31.
- On Tuesday, January 7th, Anish Patel sold 21,700 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.18, for a total value of $524,706.00.
Enliven Therapeutics Stock Up 2.2 %
Shares of ELVN stock traded up $0.45 during trading hours on Friday, hitting $20.74. 205,365 shares of the company's stock traded hands, compared to its average volume of 230,869. The stock's fifty day simple moving average is $21.59 and its two-hundred day simple moving average is $23.80. Enliven Therapeutics, Inc. has a 12-month low of $10.90 and a 12-month high of $30.03. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -10.92 and a beta of 1.04.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.07. The firm had revenue of $0.03 million during the quarter. On average, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Enliven Therapeutics
A number of hedge funds have recently added to or reduced their stakes in ELVN. Tower Research Capital LLC TRC grew its position in Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after purchasing an additional 1,114 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Enliven Therapeutics in the 4th quarter worth approximately $97,000. BNP Paribas Financial Markets bought a new stake in Enliven Therapeutics in the 4th quarter worth approximately $112,000. ExodusPoint Capital Management LP bought a new stake in Enliven Therapeutics in the 4th quarter worth approximately $200,000. Finally, Brevan Howard Capital Management LP bought a new stake in Enliven Therapeutics in the 4th quarter worth approximately $228,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
ELVN has been the topic of several recent analyst reports. BTIG Research initiated coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a "buy" rating and a $42.00 target price on the stock. Robert W. Baird raised their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $38.25.
Check Out Our Latest Analysis on ELVN
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
